TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00789815

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral index guide propofol infusion
Description: Induction:~Alfentanil: 5μg/kg slowly push. Propofol: 0.5-1.5mg/kg slowly push till BIS value 70.~Maintenance:~Propofol infusion (3\~12 mg/kg/hour) to maintain BIS around 65\~75. Alfentanil: 5μg/kg slowly push Q15min prn if severe cough.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clinical-judged midazolam administration
Description: Induction:~Alfentanil: 5μg/kg slowly push. Midazolam: 2 mg slowly push followed by increments of 2 mg/ 2min till OAA/S\* 2\~3.~Maintenance:~Midazolam: 2 mg/ 2min prn to keep OAA/S\* 2\~3 or if intolerance of procedure. Alfentanil as study arm.~\*Observer's assessment of alertness/sedation (OAA/S):~Class 5: Responds readily to name spoken in normal tone.~Class 4: Lethargic response to name called in normal tone.~Class 3: Responds only to name called loudly.~Class 2: Responds only to shaking.~Class 1: No response to shaking.
Study: NCT01946542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beet juice concentrate
Description: single dose of beet juice concentrate, roughly 70 mL

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01334788

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sleep deprivation
Description: Sleep restriction
Study: NCT00596843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: 6 one-on-one individual sessions lasting from 30 minutes to 1-hour each

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational intervention
Description: 6 1-hour sessions. 2 sessions are delivered by an interventionist and 4 sessions are delivered as videos
Study: NCT01444157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative homecare nursing
Description: The nurse helps the family assess the identified problems. Written coping strategies according to each problem is produced including actions of the patient, family member, nurse or others. At the same time the nurse keeps attention to the family members specific needs of knowledge and support when handling direct or indirect care, understanding and coping with the disease, treatment, physical, psychosocial and economical problems and the family members own physical and mental health. The nurse provides knowledge to the family on how to prevent and/or cope with problems that may occur or re-occur and/or accepts or adapt to unsolvable problems.
Study: NCT04299880

Intervention type: DRUG
Group type: OTHER
Intervention: Napabucasin
Description: Oral

Intervention type: DRUG
Group type: OTHER
Intervention: Napabucasin
Description: Oral

Intervention type: DRUG
Group type: OTHER
Intervention: Napabucasin
Description: Oral

Intervention type: DRUG
Group type: OTHER
Intervention: Napabucasin
Description: Oral

Intervention type: DRUG
Group type: OTHER
Intervention: Napabucasin
Description: Oral

Intervention type: DRUG
Group type: OTHER
Intervention: Nab-paclitaxel
Description: Intravenous

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: Intravenous

Intervention type: DRUG
Group type: OTHER
Intervention: Nivolumab
Description: Intravenous

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Intravenous

Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan
Description: Intravenous

Intervention type: DRUG
Group type: OTHER
Intervention: Leucovorin
Description: Intravenous

Intervention type: DRUG
Group type: OTHER
Intervention: 5Fluorouracil
Description: Intravenous

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Intravenous
Study: NCT03658564

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Preoperative Oral Carbohydrate Drink
Description: Patients in Oral carbohydrate group consumed 400 ml Preoperative Oral Carbohydrate Drink Nutricia preOp® (12.5% carbohydrates, 0.5kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, the Netherlands) 3 hours prior to induction of anesthesia and finished the ingestion within 20 minutes.
Study: NCT02709668

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enlyte
Description: gel cap of reduced B vitamins

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: identical to Enlyte
Study: NCT01334788

Intervention type: OTHER
Group type: OTHER
Intervention: Normal sleep
Description: These are subjects who are randomized to sleep normally.
Study: NCT00050661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclizumab
Description: Humanized anti-CD25 antibodies (anti-TAC), or placebo (saline solution), will be given as intravenous infusions on the following schedule: 2 mg/kg initially (maximum dose 200 mg) infusion given over 60 minutes, followed by a 1 mg/kg (maximum of 100 mg) infusion given over 30 minutes every two weeks thereafter for a total of 8 doses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NB-UVB
Description: total body NB-UVB at a dose that is 50% of the MED. Patients are treated 3-7 times per week, with increasing doses at every treatment if no burning occurs. This is continued until for a total of 20 ± 2 treatments total.
Study: NCT00244790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: crossover low vs high protein diet before and after weight loss
Study: NCT01865708

Intervention type: DRUG
Group type: OTHER
Intervention: Ethanol Lock
Description: Ethanol lock, utilizing 74% ethanol, will begin within 24 hours of urinary catheter placement. The lock will be done every 24 hours for 1 hour. The volume that will be instilled depends upon the fill volume of the catheter, which is imprinted by the manufacturer on each catheter. Once the alcohol is in the catheter, the proximal end of the catheter will be clamped for 1 hour. After the 1 hour dwell time, the clamp will be removed and the alcohol in the lumen of the catheter will be flushed out by the patient's own urine output.
Study: NCT01735201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 Dose A
Description: AGN-199201 Dose A applied once or twice daily to the face for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 Dose A
Description: AGN-199201 Dose A applied once or twice daily to the face for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 Dose B
Description: AGN-199201 Dose B applied once or twice daily to the face for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 Dose B
Description: AGN-199201 Dose B applied once or twice daily to the face for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 Dose C
Description: AGN-199201 Dose C applied once or twice daily to the face for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 Dose C
Description: AGN-199201 Dose C applied once or twice daily to the face for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AGN-199201 Vehicle
Description: AGN-199201 Vehicle applied once or twice daily to the face for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AGN-199201 Vehicle
Description: AGN-199201 Vehicle applied once or twice daily to the face for 28 days.
Study: NCT02944084

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rice bran extract

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Porridge in water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Porridge in milk
Study: NCT03315143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Sotagliflozin was administered as a tablet(s), orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered as a tablet(s) (identical to the sotagliflozin tablet in appearance), orally once daily.
Study: NCT01760889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 low dose range (40mg, 80mg, and 100mg)
Description: Capsule, dose titration,~* 40 mg capsule once-daily for 1 week; then~* 80 mg capsule once-daily for 4 weeks; then,~* 100 mg capsule once-daily (if unable to tolerate 100 mg dose between weeks 5 to 6, then dose to be decreased to 80 mg once-daily for the remaining 21 weeks;~* if able to tolerate 100 mg dose then will continue on 100 mg capsule once-daily for 21 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 high dose range (120mg, 140mg and 160mg)
Description: Capsule, dose titration,~* 40 mg capsule once-daily for 1 week; then~* 80 mg capsule once daily for 1 week; then~* 120 mg capsule once-daily for 1 week, then,~* 140 mg capsule once-daily for 2 weeks, then~* 160 mg once capsule once-daily (if unable to tolerate 160 mg dose between weeks 5 to 6, then dose to be decreased to 140 mg once-daily for the remaining 21 weeks;~* if able to tolerate 160 mg dose then will continue on 160 mg capsule once-daily for 21 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule a day for 26 weeks
Study: NCT03348579

Intervention type: OTHER
Intervention: Guidelines publication and application
Description: Passing recommendations on using the guidelines in the intensive care units

Intervention type: OTHER
Intervention: Guidelines publication and application
Description: Passing recommendations on using the guidelines in the intensive care units

Intervention type: OTHER
Intervention: Guidelines publication and application
Description: Passing recommendations on using the guidelines in the intensive care units

Intervention type: OTHER
Intervention: Targeted experience feedback
Description: Targeted experience feedback: On top of the standard training, the centers receive an analysis of the evolution of the practices of their center and the future of their patients between phases 1 and 2, as well as these same values for the data set. The centers are then called to conduct a meeting to determine their priority improvement points based on this audi
Study: NCT01231529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: All subjects will receive a single dose of GSK1349572 50 mg. GSK1349572 is an experimental drug in the integrase inhibitor class being developed for the treatment of HIV infection. GSK1349572 is not approved by the FDA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: All subjects will receive a single dose of GSK1349572 50 mg. GSK1349572 is an experimental drug in the integrase inhibitor class being developed for the treatment of HIV infection. GSK1349572 is not approved by the FDA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: All subjects will receive a single dose of GSK1349572 50 mg. GSK1349572 is an experimental drug in the integrase inhibitor class being developed for the treatment of HIV infection. GSK1349572 is not approved by the FDA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: All subjects will receive a single dose of GSK1349572 50 mg. GSK1349572 is an experimental drug in the integrase inhibitor class being developed for the treatment of HIV infection. GSK1349572 is not approved by the FDA.
Study: NCT01857882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Support Workshop
Description: Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients.~* Surgeon (30 mins): treatment options for breast reconstruction with indications/ contraindications, advantages / disadvantages, expected post-operative course, aesthetic result and complications with probabilities~* Registered nurse (30 mins): preparing for surgery, postoperative recovery and how to navigate the health care system~* Social worker (30 mins): values clarification exercise~* Breast reconstruction patient volunteer (30 mins) questions and answers about her personal experience
Study: NCT01266850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix®
Description: Each 1-mL dose of Rotarix® contains a suspension of at least 10\^6 median Cell Culture Infective Dose (CCID50) of live, attenuated human G1P rotavirus after reconstitution. The lyophilized vaccine contains amino acids, dextran, Dulbecco's Modified Eagle Medium (DMEM), sorbitol, and sucrose. The liquid diluent contains calcium carbonate, sterile water, and xanthan. The diluent includes an antacid component (calcium carbonate) to protect the vaccine during passage through the acid environment of the stomach. Rotarix® contains no preservatives. Once reconstituted, the vaccine will appear white and turbid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix®
Description: Each 1-mL dose of Rotarix® contains a suspension of at least 10\^6 median Cell Culture Infective Dose (CCID50) of live, attenuated human G1P rotavirus after reconstitution. The lyophilized vaccine contains amino acids, dextran, Dulbecco's Modified Eagle Medium (DMEM), sorbitol, and sucrose. The liquid diluent contains calcium carbonate, sterile water, and xanthan. The diluent includes an antacid component (calcium carbonate) to protect the vaccine during passage through the acid environment of the stomach. Rotarix® contains no preservatives. Once reconstituted, the vaccine will appear white and turbid.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix®
Description: Each 1-mL dose of Rotarix® contains a suspension of at least 10\^6 median Cell Culture Infective Dose (CCID50) of live, attenuated human G1P rotavirus after reconstitution. The lyophilized vaccine contains amino acids, dextran, Dulbecco's Modified Eagle Medium (DMEM), sorbitol, and sucrose. The liquid diluent contains calcium carbonate, sterile water, and xanthan. The diluent includes an antacid component (calcium carbonate) to protect the vaccine during passage through the acid environment of the stomach. Rotarix® contains no preservatives. Once reconstituted, the vaccine will appear white and turbid.
Study: NCT02549287

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Case Management
Description: Child welfare services as usual
Study: NCT03451591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Mononitrate XL (ISMN)
Description: Isosorbide mononitrate (ISMN), is an NO donating organic nitrate that enhances vasodilation, is widely used in ischaemic heart disease, and has no antiplatelet activity.
Study: NCT02898779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine, R-Primaquine, S-Primaquine, SR Primaquine
Description: Cohort 1: Eighteen individuals (6 per group) Cohort 2: Eighteen individuals (6 per group)~Group 1-15 mg of S-Primaquine followed by one-week washout, 15 mg of R-Primaquine followed by one week washout, and 30 mg of RS-Primaquine.~Group 2- 15 mg of R-Primaquine followed by one-week washout, 30 mg of RSPQ followed by one week washout, and 15 mg of SPQ.~Group 3- 30 mg of RS-Primaquine followed by one week washout,15 mg of SPQ followed by a one week washout, and 15 mg of RPQ.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine, R-Primaquine, S-Primaquine, SR Primaquine
Description: Cohort 1: Eighteen individuals (6 per group) Cohort 2: Eighteen individuals (6 per group)~Group 1-15 mg of S-Primaquine followed by one-week washout, 15 mg of R-Primaquine followed by one week washout, and 30 mg of RS-Primaquine.~Group 2- 15 mg of R-Primaquine followed by one-week washout, 30 mg of RSPQ followed by one week washout, and 15 mg of SPQ.~Group 3- 30 mg of RS-Primaquine followed by one week washout,15 mg of SPQ followed by a one week washout, and 15 mg of RPQ.
Study: NCT03451591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: Cilostazol is a phosphodiesterase 3-inhibitor (PDE3-inhibitor) that enhances the PGI2-cAMP system. It has weak antiplatelet effects (so low bleeding risk), reduces infarct size and reduces ageing-related decline in myelin repair in experimental models.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ISMN XL and Cilostazol
Description: Cilostazol is a phosphodiesterase 3-inhibitor (PDE3-inhibitor) that enhances the PGI2-cAMP system. It has weak antiplatelet effects (so low bleeding risk), reduces infarct size and reduces ageing-related decline in myelin repair in experimental models. Isosorbide mononitrate (ISMN), is an NO donating organic nitrate that enhances vasodilation, is widely used in ischaemic heart disease, and has no antiplatelet activity.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Neither ISMN nor cilostazol
Description: Neither isosorbide mononitrate nor Cilostazol administered for the entire duration of the study.
Study: NCT01391208

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: GI heptapeptide
Description: GI heptapeptide, Linear, 7 amino acid peptide sequence ASYNYDA with a 5-FITC tag and NH2 terminus. Chemical Formula: Ala1-Ser2-Tyr3-Asn4-Tyr5-Asp6-Ala7-Gly8- Gly9-Gly10-Ser11-Lys12 (5-FITC) -NH213.Investigational Agent Manufacturer: CPC Scientific, 1245 Reamwood Ave, Sunnyvale, CA 94089 Investigational Agent information: Lot Number: 10031701, M.W. 1577.6, 97.2% pure. Stored at -20C Yellow, lyophilized powder in single use amber vials. 5-FITC is light-sensitive, therefore stored protected from light. Manufactured under cGMP with Certificate of Analysis (COA) provided.
Study: NCT02342158

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy or surgical sampling
Study: NCT01869790

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Different fat types
Description: Saturated, monounsaturated fats
Study: NCT00608010

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vitrification
Description: Embryos were vitrified according to a previously described technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Slow freezing
Description: Embryos were frozen with slow freezing technique
Study: NCT02342158

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sampling
Study: NCT04032535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6523
Description: CHF6523 is a PI3K inhibitor (phosphoinositide3-kinase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6523
Description: CHF6523 is a PI3K inhibitor (phosphoinositide3-kinase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6523
Description: CHF6523 is a PI3K inhibitor (phosphoinositide3-kinase)
Study: NCT03637543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an antibody inhibitor of the programmed death-1 (PD-1) pathway. By blocking PD-1, this medication may allow the immune system to recognize and fight cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an antibody inhibitor of the programmed death-1 (PD-1) pathway. By blocking PD-1, this medication may allow the immune system to recognize and fight cancer
Study: NCT04526535

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ultrasound
Description: Lung ultrasound performed with a portable device with an 8 zones protocol within the first 24 hours after and ST-segment elevation acute myocardial infarction

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ultrasound
Description: Lung ultrasound performed with a portable device with an 8 zones protocol within the first 24 hours after and ST-segment elevation acute myocardial infarction
Study: NCT03774901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: intravenous 10 mg/kg every 2 weeks
Study: NCT02278068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metabolic Neuromodulation System (MNS)
Description: Prospective, First-in-Human (FIH), multi-center, non-randomized trial to evaluate the initial safety and performance of hepatic sympathetic denervation to aid in glycemic control.
Study: NCT00705133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil
Description: For both SQ and IV routes, treprostinil will be started in the hospital at 1ng/kg/min and titrated up by 1ng/kg/min every 1-3 days as tolerated
Study: NCT01799590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate tablets will be administered orally in the dose range of 50 to100 milligram per day (mg/day). Dose will be increased or decreased as per Investigator's discretion. Maximum daily dose limit will be 200 mg.
Study: NCT01783418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Intervention
Description: Mindfulness-based intervention adapted for teenagers

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Intervention
Description: Mindfulness-based intervention adapted for teenagers
Study: NCT04835818

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Provide the panel report to the primary care physician
Description: Point-of-care Multiplex PCR Respiratory Panel (BIOFIRE FilmArray) and Pneumonia Panel results (BIOFIRE FilmArray)
Study: NCT01621126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-operative neuromonitoring (XLTEK/NATUS EP Protektor)
Description: Device: Intra-operative neuromonitoring A XLTEK/NATUS EP Protektor machine (at MGH) or a Cadwell Cascade Elite neuromonitoring machine (at BWH), both FDA approved for intra-operative neuromonitoring, will deliver the electrical stimulus applied transcranially to stimulate the motor cortex, while motor evoked responses will be recorded from different myotomes from both upper limbs. Also the same equipment will deliver electrical stimulus to stimulate peripherally the median and ulnar nerves at the wrists, with recording of the thalamocortical potentials in the scalp channels.
Study: NCT02016105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP2017 Adalimumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humira ® Adalimumab
Study: NCT05193539

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented reality and virtual reality rehabilitation
Description: This group underwent augmented reality and virtual reality rehabilitation with 4 different systems.~The RAPAEL Smart Glove® is a wearable sensory system that contains a single 9-axis movement and position sensor with 3 acceleration channels, 3 angular rate channels, and 3 magnetic field channels that measures wrist movements, and 5 bending sensors that measure finger movements. The RAPAEL Smart Board® is a rehabilitation system used to improve arm function by practicing gravity-compensated movements. The RehabMaster® is a game-based Kinect sensor AR rehabilitation system which uses a 3D camera to digitize patient movements and quickly analyze their range of motion, speed, motion angle, and movement cycles. rehabilitation exercise using games to encourage active arm and trunk movements and promote successful rehabilitation. The COG-Trainer® is a VR system that uses a training device synchronized with the screen through simulation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional occupational therapy
Description: The group underwent standard ocupational therapy, such as range of motion and strengthening exercises for the affected upper extremity, table-top activities, and training for activities of daily living.